← All trials
NCT05939076
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 21, 2023
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2028
- First posted
- Jul 11, 2023
- Last posted
- Jul 11, 2023
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Orebro UniversityLead sponsor
- Orebro UniversityReponsible party - principal investigator
- Swedish Heart Lung FoundationCollaborator
- The Swedish Research CouncilCollaborator
- Uppsala UniversityCollaborator
- Orebro UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.